Effect of Glucagon-Like Peptide-1 on Epicardial Fat in Patients with Type 2 Diabetes Mellitus and Obesity
https://doi.org/10.31550/1727-2378-2023-22-8-47-50
Abstract
Aim. To evaluate the effect of a hypoglycemic drug from the group of glucagon-like peptide-1 agonists on epicardial fat thickness in patients with type 2 diabetes mellitus and obesity.
Design. Open pilot study.
Materials and methods. The study included 30 patients (12 women and 18 men) with type 2 diabetes mellitus and obesity of varying severity. 2 patients had a history of myocardial infarction, 20 patients had arterial hypertension of varying severity. To current therapy with oral hypoglycemic agents Dulaglutide was added with drugs for intensification at a dose of 1.5 mg once a week. At baseline and one year later, along with routine laboratory parameters, we assessed the level of glycated hemoglobin, C-reactive protein, anthropometric indicators (body weight, body mass index, waist circumference), echocardiography with determination of epicardial fat thickness, and bioimpedance measurements.
Results. After 12 months of therapy, patients showed a significant decrease in the level of glycated hemoglobin by 0.95% (0.63–1.29%; p < 0.05). Improved performance of carbohydrate metabolism was accompanied by a statistically significant decrease in body weight by 0.96% (0.83–1.1%; p < 0.005), epicardial fat thickness by 0.89 cm (0.08–1.00 cm; p < 0.001) and the amount of adipose tissue according to bioimpedance measurements by 0.88 kg (0.29–0.98 kg; p < 0.05).
Conclusion. Intensification therapy with the GLP-1 receptor agonist dulaglutide led to a significant improvement in carbohydrate metabolism and a decrease in the amount of fat, both total and epicardial, which could potentially reduce the risk of developing cardiovascular events in patients with type 2 diabetes and obesity.
About the Authors
D. G. Gusenbekova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
2/1 build. 1 Barrikadnaya str., Moscow, 125993
A. S. Ametov
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
2/1 build. 1 Barrikadnaya str., Moscow, 125993
O. D. Ostroumova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
2/1 build. 1 Barrikadnaya str., Moscow, 125993
References
1. Braescu L., Gaspar M., Buriman D. et al. The role and implications of epicardial fat in coronary atherosclerotic disease. J. Clin. Med. 2022;11(16):4718. DOI: 10.3390/jcm11164718
2. Iacobellis G. Epicardial fat links obesity to cardiovascular diseases. Prog. Cardiovasc. Dis. 2023:S0033-0620(23)00036-1. DOI: 10.1016/j.pcad.2023.04.006
3. Couselo-Seijas M., Rodríguez-Mañero M., González-Juanatey J., Eiras S. Updates on epicardial adipose tissue mechanisms on atrial fibrillation. Obes. Rev. 2021;22(9):e13277. DOI: 10.1111/obr.13277
4. Patel V., Patel J. Cellular cross talk between epicardial fat and cardiovascular risk. J. Basic Clin. Physiol. Pharmacol. 2022;33(6):683–694. DOI: 10.1515/jbcpp-2022-0230
5. Mazurek T., Opolski G. Pericoronary adipose tissue: a novel therapeutic target in obesity-related coronary atherosclerosis. J. Am. Coll. Nutr. 2015;34(3):244–254. DOI: 10.1080/07315724.2014.933685
6. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat. Rev. Endocrinol. 2015;11(6):363–371. DOI: 10.1038/nrendo.2015.58
7. Iacobellis G., Baroni M. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J. Endocrinol. Invest. 2022;45(3):489–495. DOI: 10.1007/s40618-021-01687-1
8. Berg G., Barchuk M., Lobo M., Nogueira J. Effect of glucagonlike peptide-1 (GLP-1) analogues on epicardial adipose tissue: a meta-analysis. Diabetes Metab. Syndr. 2022;16(7):102562. DOI: 10.1016/j.dsx.2022.102562
9. Iacobellis G., Camarena V., Sant D. W., Wang G. Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes. Horm. Metab. Res. 2017;49(08):625–630. DOI: 10.1055/s-0043-109563
10. Lima-Martínez M., Paoli M., Rodney M. et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine. 2016;51:448–455. DOI: 10.1007/s12020-015-0710-y
11. Neeland I., Ross R., Després J. et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–725. DOI: 10.1016/S2213-8587(19)30084-1
12. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J. Am. Coll. Cardiol. 2018;71(20):2360–2372. DOI: 10.1016/j.jacc.2018.03.509
13. Villasante Fricke A., Iacobellis G. Epicardial adipose tissue: clinical biomarker of cardio-metabolic risk. Int. J. Mol. Sci. 2019;20(23):5989. DOI: 10.3390/ijms20235989
14. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100(10):1132–1133. DOI: 10.1161/01.cir.100.10.1132
15. Boncler M., Wu Y., Watala C. The multiple faces of C-reactive protein — physiological and pathophysiological implications in cardiovascular disease. Molecules. 2019;24(11):2062. DOI: 10.3390/molecules24112062
Review
For citations:
Gusenbekova D.G., Ametov A.S., Ostroumova O.D. Effect of Glucagon-Like Peptide-1 on Epicardial Fat in Patients with Type 2 Diabetes Mellitus and Obesity. Title. 2023;22(8):47-50. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-8-47-50
Views:
11
Email this article 